Khanna, Navin (2020) CORRESPONDENCE Tetravalent Dengue Vaccine in Healthy Children New England Journal of Medicine, 382 (18). pp. 1769-1771. ISSN 0028-4793
Full text not available from this repository.
Official URL: http://doi.org/10.1056/nejmc2000987
Related URL: http://dx.doi.org/10.1056/nejmc2000987
Abstract
To the Editor: The tetravalent dengue vaccine candidate (TAK-003, Takeda) in the trial by Biswal et al. (Nov. 21 issue)1 looks promising and has better overall efficacy than CYD-TDV (Dengvaxia, Sanofi Pasteur).2 Two major improvements in this trial are that all the participants underwent serologic testing before randomization and there was no need to do a post hoc analysis according to age groups. However, it is too early to conclude that TAK-003 will be better than CYD-TDV.
| Item Type: | Article |
|---|---|
| Source: | Copyright of this article belongs to Massachusetts Medical Society. |
| ID Code: | 123857 |
| Deposited On: | 19 Oct 2021 06:25 |
| Last Modified: | 19 Oct 2021 06:25 |
Repository Staff Only: item control page
